Site Logo

Hello, you are using an old browser that's unsafe and no longer supported. Please consider updating your browser to a newer version, or downloading a modern browser.

PTX-014 (Undisclosed Indication)

Palvella’s preclinical PTX-014 program will be addressing a serious, rare genodermatoses with no FDA approved treatments.

Clinical Trials

To be announced

Clinical Trial Requirements:

To be announced

Resources for PTX-014

National Organization for Rare Disorders

NORD is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with its more than 280 patient organizations members, is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.

dark arrow